China-based medical imaging services provider Keya Medical Technology has closed an RMB200m ($30.2m) series C round featuring pharmaceutical and medical products group Tasly, DealStreetAsia reported yesterday.
The round was led by venture capital group IDG Capital and included VC firms Source Code Capital and Alwin Capital.
Keya produces medical imaging software with a focus on diagnosing coronary heart disease. The funding will go to product development as the company targets international growth.
VC firm GGV Capital led a $20m series B-plus round for Keya that closed in August this year according to DealStreetAsia.
The August funding came six months after a $4.3m series B round backed by internet group Kunlun Wanwei as well as Shanghai International Group’s Shanghai Guofang Parent Fund, IDG Capital and Yahui Capital. Keya’s earlier investors also include Alwin Capital, Ambrum Capital and Hangzhou Jingchen Investment.